TERN240920P11000
- 1.40
- -0.30-17.65%
Terns Pharmaceuticals Newsroom
Terns Pharma Analyst Ratings
BMO Capital Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Raises Target Price to $26
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Aura Biosciences Inc (AURA) and Terns Pharmaceuticals (TERN)
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $10
Terns Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Terns Pharma Analyst Ratings
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
Jefferies Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Raises Target Price to $30
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Raises Target Price to $20
Buy Rating on Terns Pharmaceuticals: Strong TERN-601 Trial Results and Market Valuation Justify Increased Price Target
TD Cowen Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $15
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $15
Market Outperform Rating for Terns Pharmaceuticals With a $15 Price Target Based on TERN-501 Clinical Trials Progress
BMO Capital Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $19
Jefferies Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $22
Jefferies Sticks to Their Buy Rating for Terns Pharmaceuticals (TERN)
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Announces Target Price $10
JMP Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $15
Buy Rating for Terns Pharmaceuticals Amid Forthcoming Milestones and Financial Stability